Long-term follow-up of patients undergoing resection of tnm stage i colorectal cancer: an analysis of tumour and host determinants of outcome by Mansouri, David et al.
  
 
 
 
 
Mansouri, D., Powell, A., Park, J. H., McMillan, D. C., and Horgan, P. G. (2016) Long-
term follow-up of patients undergoing resection of tnm stage i colorectal cancer: an 
analysis of tumour and host determinants of outcome. World Journal of Surgery, 40(6), 
pp. 1485-1491. 
 
   
There may be differences between this version and the published version. You are 
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
http://eprints.gla.ac.uk/120298/ 
     
 
 
 
 
 
 
Deposited on: 27 July 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
 1 
Long-term follow-up of patients undergoing resection of TNM Stage I colorectal 
cancer: An analysis of tumour and host determinants of outcome 
 
 
 
David Mansouri1, Arfon G Powell1,2, James H Park1, Donald C McMillan1, Paul G 
Horgan1 
 
1. Academic Unit of Colorectal Surgery, University of Glasgow, Glasgow 
Royal Infirmary, Glasgow 
 
2. Institute of Cancer and Genetics, Cardiff University, Heath Park, Cardiff 
 
 
Running title: Long- term outcome Stage I colorectal cancer 
 
Keywords: Colorectal cancer, systemic inflammatory response, Stage I disease,  
 
Word count: 2743571 words 
 
The authors declare no conflicts of interest 
 
 
Correspondence to: 
Mr David Mansouri 
Academic Unit of Colorectal Surgery,  
College of Medical, Veterinary and Life Sciences, 
University of Glasgow 
Rm 2.57 New Lister Building 
Glasgow Royal Infirmary 
10-16 Alexandra Parade 
G31 2ER 
 
Tel: +44 (0)141 211 8653 
David.Mansouri@glasgow.ac.uk 
 
 
 
 
 
 2 
Abstract 
Background 
Screening for colorectal cancer improves cancer specific survival (CSS) through the 
detection of early stage disease, however its impact on overall survival (OS) is 
unclear. The present study examined tumour and host determinants of outcome in 
TNM Stage I disease. 
 
Methods 
All patients with pathologically confirmed TNM Stage I disease across 4 hospitals in 
the North of Glasgow between 2000 and 2008 were included. The preoperative 
modified Glasgow Prognostic Score (mGPS) was used as a marker of the host 
systemic inflammatory response (SIR). 
 
Results 
There were 191 patients identified, 105 (55%) were males, 91 (48%) were over the 
age of 75 years and 7 (4%) patients underwent an emergency operation.  In those with 
a pre-operative CRP result (n=150), 35 (24%) patients had evidence of an elevated 
mGPS. Median follow-up of survivors was 116 months (minimum 72 months) during 
which 88 (46%) patients died; 7 (8%) had postoperative deaths, 15 (17%) had cancer-
related deaths and 66 (75%) had non cancer-related deaths. 5-year CSS was 95% and 
OS was 76%. On univariate analysis, advancing age (p<0.001), emergency 
presentation (p=0.008) and an elevated mGPS (p=0.012) were associated with 
reduced OS. On multivariate analysis, only age (HR = 3.611, 95% CI: 2.049–6.365, 
p<0.001) and the presence of an elevated mGPS (HR = 2.173, 95% CI: 1.204–3.921, 
p=0.010) retained significance. 
 
Conclusions 
In patients undergoing resection for TNM Stage I colorectal cancer, an elevated 
mGPS was an objective independent marker of poorer OS.  These patients may 
benefit from a targeted intervention.  
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Introduction  
Population screening for colorectal cancer using the faecal occult blood test 
(FOBt) has been shown to improve cancer specific mortality through the detection of 
early stage disease [1-3]. Through this detection of early stage tumours, such 
screening programmes have the potential to change the entire landscape of the 
management and outcome of colorectal cancer. For example, studies in the pre-
screening era noted that less than 20% of all patients presented with TNM Stage I 
disease [4,5]. However, it has been shown that TNM Stage I tumours can account for 
approximately 50% of colorectal cancers detected through FOBt screening 
programmes [6-8]. Hence, an overall stage-shift towards early stage disease is 
anticipated over the next decade [9].  
Cancer outcome following a diagnosis of TNM Stage I colorectal cancer is very 
good, and an average 5-year cancer specific survival of over 90% is widely reported 
[10]. As such, adjuvant chemotherapy is not recommended in these patients [11,12]. 
Nevertheless, some will develop metastatic disease and ultimately succumb to their 
illness and others will die of alternate causes, such as cardiovascular disease. This 
would be increasingly relevant to those detected through screening, as while 
screening improves cancer specific mortality, no effect on overall survival has been 
shown on mature follow up [13].  
Many risk factors associated with a diagnosis of colorectal cancer are similar to 
those for cardiovascular disease [14], which is the leading cause of death in 
individuals over the age of 50 [15]. It is now increasingly recognised that independent 
of TNM Stage, there are host factors that may be of importance in predicting 
outcome. In particular, the presence of an elevated systemic inflammatory response 
[16,17] as evidenced by an alteration in circulating acute phase proteins, such as C-
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reactive protein (CRP) and albumin (modified Glasgow Progostic Score (mGPS)), is 
associated not only with poorer outcome in colorectal cancer, but more recently it has 
been linked to all-cause mortality in a large incidentally sampled cohort [18]. There is 
a paucity of evidence examining tumour and, in particular, host factors in determining 
outcome specifically in patients with TNM Stage I colorectal cancer. This is 
something that is of increasing importance in the post-screening era. 
 The aim of the present study was to examine tumour and host determinants of 
outcome in patients undergoing resection for TNM Stage I colorectal cancer with 
mature follow-up.  
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Materials and Methods 
From January 2000 to December 2008 (inclusive), all patients undergoing a 
resection, with pathologically confirmed TNM Stage I disease, across four hospitals 
in the north of Glasgow were identified. Data was collected in both a prospective 
(Glasgow Royal Infirmary) and retrospective (Stobhill Hospital, Western Infirmary, 
Gartnavel General Hospital) manner. Any patient with a synchronous cancer, 
inflammatory bowel disease or who had received neo-adjuvant therapy was excluded. 
Those with their disease managed entirely endoscopically, without formal colonic or 
rectal resection, were also excluded from the study.  
Tumours were staged according to the conventional tumour node metastasis 
(TNM) classification (5th Edition)[19]. Further details on high-risk tumour features, 
such as the presence of venous invasion [20], poor differentiation [21] or those in 
whom less than 12 lymph nodes were examined [21] were extracted from pathology 
reports. Those with inadequate information on the number of nodes examined in 
pathology reports were excluded from the analysis. 
The mGPS was used as an estimate of the SIR as has been described 
previously, using pre-operative blood results taken most immediately and not more 
than 1 month prior to surgery [22]. Bloods were taken as routine care at preoperative 
assessment using standard aseptic technique and processed according to standard 
laboratory protocols. The mGPS was constructed as follows; Briefly, patients with a 
CRP < 10 mg/L were allocated a score of 0, a CRP >10 mg/L and albumin > 35g/L a 
score of 1 and a CRP >10mg/L and albumin <35g/L a score of 2. Due to limited 
events during follow-up, for survival analysis the mGPS was further dichotomised 
into being elevated (mGPS = 1 or 2) or not elevated (mGPS = 0).  
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Survival was determined from both individual electronic patient records and 
by matching patients to the Registrar General (Scotland). Date of censor was 12th 
December 2014.  Overall survival (OS) was the primary outcome measure and was 
calculated from date of surgery until date of death. Cancer specific survival (CSS) 
was calculated from date of surgery until date of death from recurrent or metastatic 
colorectal cancer. A post-operative death was defined as a death within 30 days of 
operation.   
The study was discussed and approved by the local research and ethics 
committee.  
 
Statistical analyses 
The relationship between clinicopathological features and survival was 
examined using Kaplain-Meier log-rank survival analysis and univariate Cox 
proportional hazards regression to calculate hazard ratios (HR) and 95% confidence 
intervals (95% CI). Statistically significant variables on univariate analysis were then 
taken forward into a multivariate model using a backwards conditional method. 
Associations between variables were examined using the Chi-squared test. Fisher’s 
exact test was used for assessing associations where the expected individual cell 
counts were less than 5. A value of p<0.05 was considered statistically significant. 
Statistical analysis was performed using SPSS software (SPSS Inc., Chicago, IL, 
USA) 
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Results 
 A total of 191 patients were identified and included in the study. There were 
105 (55%) males, 91 (48%) were over the age of 75 years and 7 (4%) patients 
underwent an operation as an emergency. Of the emergency operations, 5 (71%) 
patients underwent a right hemicolectomy due to an obstructing caecal tumour, 1 
(14%) patient underwent a sigmoid colectomy for concurrent diverticulitis and 1 
(14%) patient underwent a panproctocolectomy following an iatrogenic caecal 
perforation during colonoscopic diagnosis of an early rectal tumour.  In those with a 
pre-operative CRP result (n=150), 35 (24%) patients had evidence of an elevated 
mGPS (Table 1). 
 The median follow-up of survivors was 116 months with a minimum follow-
up of 72 months. During follow-up 88 (46%) patients died of which 7 (8%) were 
postoperative deaths, 15 (17%) were colorectal cancer-related deaths and 66 (75%) 
were non- colorectal cancer-related deaths.  The causes of non-colorectal cancer-
related deaths were; 20 (30%) patients non-colorectal cancer, 15 (23%) patients 
cardiovascular disease, 8 (12%) patients respiratory disease, 8 (12%) patients 
cerebrovascular disease and 15 (23%) patients miscellaneous causes. This The 1, 2 
and 5 year resulted in a 5 year CSS of 95% and a 5 year OS of 76% was 98%, 95% 
and 95%, and 90%, 83% and 76% respectively. Excluding postoperative deaths, on 
univariate analysis, advancing age (p<0.001), emergency presentation (p=0.008) and 
an elevated mGPS (p=0.012) were associated with reduced OS. On multivariate 
analysis, only age (HR = 3.611, 95% CI:2.049 - 6.365, p<0.001) and the presence of 
an elevated mGPS (HR = 2.173, 95% CI:1.204 – 3.921, p=0.010) retained 
significance (Table 2, Figure 1).  
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There was an association between an elevated mGPS and emergency 
presentation (p=0.040). In view of this, survival in elective procedures was examined 
independently (Table 3). Excluding postoperative deaths, on univariate analysis, 
advancing age (p<0.001) and an elevated mGPS (p=0.034) were associated with 
reduced OS. On multivariate analysis, both age (HR = 3.503. 95% CI:1.980 – 6.196, 
p<0.001) and the presence of an elevated mGPS (HR = 2.104, 95% CI:1.155 – 3.835, 
p= 0.015) retained significance (Table 3). There were no further associations between 
the presence of an elevated mGPS and additional clinicopathological variables (Table 
4). The unadjusted difference in mean OS between those with an elevated mGPS and 
those without was 31 months (Table 4).  
 Data was further stratified to assess any temporal trends that may have 
developed over the timeframe. Comparing patients operated on between 2001 and 
2004 to those operated on between 2005 and 2008, there were no differences in age 
(p=0.548), sex (p=0.292), mode of presentation (p=0.345), site of tumour (p=0.149), 
t-stage (p=0.969), tumour differentiation (p=0.656) or the presence of an elevated 
mGPS (p=0.520). Patients operated on between 2001 and 2004 were more likely to 
have less than 12 lymph nodes examined (61% vs 44%, p=0.020) and there was a 
trend towards a lower venous invasion rate (17% vs 28%, p=0.073). Date of operation 
was not associated with OS (Tables 2 & 3).  
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Discussion 
 The results of the present study show that with mature follow-up, although 
cancer specific survival was 95%, overall survival was 76% in patients undergoing 
resection for TNM Stage I colorectal cancer. Furthermore, in these patients, the 
presence of an elevated SIR, as measured by the mGPS, was associated with poorer 
outcome. Taken together, this supports the argument that the SIR can be used as a 
means of identifying patients with a poorer outcome even within very early stage 
colorectal cancer. 
The results of the present study confirm previous work that has shown that 
long-term oncological outcome in TNM Stage I disease is excellent [10]. However, a 
significant amount of patients will die of other causes and there is a paucity of 
evidence focussing on OS, which is ultimately of most relevance in patient outcome. 
In particular, to our knowledge, there have been no studies examining the relationship 
between the SIR and OS in TNM Stage I disease. Given that the SIR has been shown 
to be associated with adverse outcomes in both cardiovascular disease as well as 
cancer, it may represent a nexus from which overall survival may be predicted and 
improved in this patient cohort. For example, several large prospective cohort studies 
have identified inflammatory mediators including as C-RP and albumin, as being 
predictive of both all cause, cancer-specific mortality and cardiovascular mortality in 
the over 50s [23,24]. 
It is of interest to compare this to previous work in our geographical area that 
has identified that age and emergency presentation are associated with survival in 
Stage II disease [25]. In the present study when adjusted for the SIR, as evidenced by 
mGPS, emergency presentation failed to retain prognostic significance. This is in 
contrast to a previous study, predominantly in Stage II disease, that had shown that 
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while emergency presentation and the SIR were linked, they both represented 
independent predictors of CSS [26]. This disparity is likely due to the focus on OS in 
the present study and the low number of cancer-related deaths. Furthermore, it may be 
speculated that within very early stage disease, emergency presentation, and its 
relationship with OS, represents a surrogate for a pro-inflammatory state that the 
mGPS more accurately recapitulates.   
In addition to the long-term sequelae, there are short-term consequences of an 
elevated preoperative SIR that are important to consider. In the present study the 
overall postoperative mortality of 3.7% was in line with a large scale audit within the 
UK [27]. However, colorectalColorectal resections can be associated with significant 
morbidity including both infective and non-infective postoperative complications. The 
preoperative SIR has been previously shown to be predictive of the development of a 
postoperative infection [287] and is associated with an elevated postoperative SIR, as 
measured by CRP [298]. Such a rise in the postoperative CRP is associated with 
higher rates of both surgical-site and remote infective complications [3029]. In 
particular, in a recent meta-analysis the use of Day 3 CRP as a predictor of an 
anastomotic leak in the postoperative course at a threshold of 172 mg/l was found to 
have a negative predictive value of 97% [310].  
It is important to identify consider why individuals may have an elevated 
preoperative SIR in order to potentially identify a targets for intervention. The SIR 
has been linked to a number of patient-related factors including smoking [321], 
diabetes [330] and obesity [343] and cardiovascular disease [23]. In the context of 
colorectal cancer specifically, the SIR has been found to be associated with 
preoperative impaired patient physiology, including an elevated physiological and 
operative severity score for the enumeration of mortality and morbidity (POSSUM) 
Formatted: Indent: First line:  1.27
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[35]., A full assessment of comorbidity was not carried out in the present study. 
However, the SIR has previously been shown to determine outcome independent of 
comorbidity [35]. Therefore, although there is a relationship between the SIR and 
comorbid disease their impact on survival on survival is likely to be complex and 
reflects the interaction between the tumour and the host. It is proposed that the SIR 
represents an objective global assessment of the patient and as such may be a 
therapeutic target for potential intervention [36]. 
however, it has been shown that it can determine outcome independent of 
comorbidity [34]. Therefore, to equate the SIR to a mere surrogate of comorbid 
disease would be to oversimplify a more complex interaction between tumour and 
host. Assessment of comorbidity was not available in the population included in the 
present study and therefore this was not included as a covariate. It is proposed, 
however, that the SIR represents a global assessment of the patient and may be a 
therapeutic target for potential intervention [35].  
 A diagnosis of cancer has been identified as a ‘teachable moment’ 
whereby individuals are more receptive to changes in risk-related lifestyle and 
behaviour [376]. Indeed, the recently published BeWEL study has identified that a 
weight loss programme can be successfully instigated in patients who have adenomata 
identified at colonoscopy following a positive FOBt screening test [387]. The authors 
reported that interventions including exercise not only reduced weight, but improved 
blood pressure and glucose metabolism markers after 1 year. The SIR was not 
reported on within the BeWEL study, however weight control and exercise 
programmes have previously been shown to reduce the SIR [398]. The present study 
identifies a subgroup of patients that have a poorer outcome and hence may be 
suitable for targeting with such a programme. Further studies could include the 
Formatted: Indent: First line:  1.27
cm
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instigation of such a rehabilitation programme, in a manner not dissimilar to cardiac 
rehabilitation, which is now a standard of care for patients who have undergone a 
cardiac event. 
 In addition to lifestyle measures such as diet and exercise, there is potential to 
manipulate the SIR through pharmacological methods. There is evidence that both 
statins [4039,410] and aspirin [421] use can reduce circulating CRP levels and this 
can have a positive effect on outcomes from cardiovascular disease [343]. 
Furthermore, these medications have also been shown to have a potential role in the 
prevention of colorectal cancer development [432,443] and progression [454]. The 
argument for a ‘polypill’, combining blood pressure and cholesterol lowering 
medication as well as antiplatelet treatments, has previously been made to reduce 
deaths from cardiovascular disease [465] however its benefits remain uncertain when 
used in a relatively unselected patient population [476]. Prospective studies are 
required to assess whether these medications should be routinely recommended in 
early stage colorectal cancer due to these combined effects of cardiovascular 
protection and chemoprevention.  
 
 
Strengths & Limitations 
The strengths of the present study include the relatively large numbers with 
long-term follow-up. In addition, the present study has included detailed high-risk 
tumour factors such as the presence of venous invasion. The main limitation of the 
study is that  this is a historic cohort captured over a prolonged timeframe. As such, 
temporal changes in staging and management may have taken place. Indeed, the 
proportion of patients with less than 12 nodes examined was lower in those operated 
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on in earlier years. Such a problem is inherent when examining early stage disease 
that was uncommon prior to the introduction of screening. However, this has been 
adjusted for within survival analysis and it is reassuring that date of operation was not 
associated with OS in this cohort. In addition, applicability of the findings to a screen-
detected cohort may be questionable. Patients with screen-detected tumours differ in 
terms of patient demographics and comorbidities, and as such may have different 
determinants of outcome [487]. Due to the relatively recent introduction of population 
screening in the UK and a lack of mature follow-up of screen-detected TNM Stage I 
disease this remains to be determined. Nevertheless, it should be noted that, despite 
the introduction of national screening programmes, a large proportion of patients 
continue to present through alternative routes [49]Due to the relatively recent 
introduction of population screening in the UK, mature follow-up of screen-detected 
TNM Stage I disease is not yet possible..    
Within the pathological reporting of specimens there were a large number of 
patients who had suboptimal lymph node examination and hence may be perceived as 
being understaged. The present study has shown this to be associated with historic 
changes in processing of specimens. In addition, it may also be due to the relatively 
high proportion of rectal tumours in this cohort. However, if this were to have 
introduced bias of understaging then it would be expected that outcomes would be 
poorer in this group, which was not the case. Finally, a perceived limitation may be 
the lack of cancer specific survival analysis within the present study. However, due to 
the small proportion of cancer deaths in this cohort, such analysis is problematic. 
Also, the relevance of CSS to the individual patient is limited and, particularly in the 
screened population, recommendations for reporting effects on OS have been made 
[5048].  
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In summary, patients undergoing resection for TNM Stage I colorectal cancer 
have an excellent oncological outcome, however only around three quarters of our 
cohort were alive at 5 years. The presence of an elevated preoperative SIR, as 
measured by the mGPS, is an objective independent marker that identifies patients 
with poorer overall survival and potentially identifies a subgroup that may benefit 
from targeted pharmacological or lifestyle interventions aimed at reducing systemic 
inflammation.  
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Table 1: Baseline characteristics of patients undergoing resection for TNM Stage 
I colorectal cancer 
 
 
 All patients 
n(%) 
 
 191 
Age  
    <75 100 (52) 
    >75 91 (48) 
Sex   
    Female 86 (45) 
    Male 105 (55) 
Mode of presentation  
    Emergency 7 (4) 
    Elective 184 (96) 
Tumour Site  
    Colon 122 (64) 
    Rectum  69 (36) 
T-stage  
    1 54 (28) 
    2 137 (72) 
Venous invasiona  
    Present 37 (22) 
    Absent 130 (78) 
Differentiation  
    Poor 3 (2) 
    Moderate/well 188 (98) 
Less than 12 lymph nodes   
    Yes 102 (53) 
    No 89 (47) 
mGPSb  
    0 115 (77) 
    1 22 (15) 
    2 13 (9) 
Date of operation  
    2001 - 2004 103 (54) 
    2005 - 2008  88 (46) 
Outcome at date of censor  
    Alive 103 (54) 
    Postoperative death 7 (4) 
    Cancer-related death 15 (8) 
    Non cancer-related death 66 (35) 
 
 
a Data complete 167 (87%) patients 
b mGPS = modified Glasgow Prognostic Score. Data complete 150 (79%) patients
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Table 2: Factors associated with overall survival following resection for TNM Stage I colorectal cancer (excluding post operative deaths) 
 
 
 
 
 Univariate survival 
analysis 
 
HR (95% C.I.) 
 
p-value 
Multivariate 
survival analysis 
 
HR (95% C.I.) 
 
 
p-value 
     
Age (<75 / >75) 3.722 
(2.310 – 5.996) 
<0.001 3.611 
(2.049 – 6.365) 
<0.001 
Sex    (Female / Male) 0.895 
(0.579 – 1.385) 
0.620 -  
Mode of presentation (Elective / Emergency) 3.443 
(1.387 – 8.543) 
0.008 1.036 
(0.240 – 4.469) 
0.962 
Tumour Site (Colon / Rectum) 0.915 
(0.580 – 1.442) 
 -  
T-stage (1 / 2) 1.104 
(0.676 – 1.804) 
0.692 -  
Venous invasion (No / Yes) 1.304 
(0.762 – 2.229) 
0.333 -  
Differentiation    (moderate-well / poor) 1.661 
(0.407 – 6.778) 
0.479 -  
Less than 12 lymph nodes (No / Yes) 1.122 
(0.721 – 1.745) 
0.610 -  
mGPS  (0 / 1+2) 2.076 
(1.172 – 3.677) 
0.012 2.173 
(1.204 – 3.921) 
0.010 
Date of operation (2001-2004 / 2005 – 2008) 1.233 
(0.769 – 1.976) 
0.385 -  
 
 
 
  
 24 
 
Table 3: Factors associated with overall survival following resection for TNM Stage I colorectal cancer (excluding emergency 
presentation and post operative deaths) 
 
 
 
 Univariate survival 
analysis 
 
HR (95% C.I.) 
 
p-value 
Multivariate 
survival analysis 
 
HR (95% C.I.) 
 
 
p-value 
     
Age (<75 / >75) 3.634 
(2.228 – 5.926) 
<0.001 3.503 
(1.980 – 6.196) 
<0.001 
Sex    (Female / Male) 0.832 
(0.530 – 1.305) 
0.423 -  
Tumour Site (Colon / Rectum) 0.939 
(0.589 – 1.498) 
0.791 -  
T-stage (1 / 2) 1.042 
(0.634 – 1.713) 
0.871 -  
Venous invasion (No / Yes) 1.343 
(0.772 – 2.336) 
0.297 -  
Differentiation    (moderate-well / poor) 1.745 
(0.427 – 7.130) 
0.438 -  
Less than 12 lymph nodes (No / Yes) 1.041 
(0.661 – 1.641) 
0.861 -  
mGPS  (0 / 1+2) 1.908 
(1.050 – 3.467) 
0.034 2.104 
(1.155 – 3.835) 
0.015 
Date of operation (2001-2004 / 2005 – 2008) 1.229 
(0.753 – 2.004) 
0.410 -  
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Table 4: Relationship between clinicopathological factors, overall survival (OS) and 
the modified Glasgow Prognostic Score (mGPS) in patients undergoing resection for 
TNM Stage I colorectal cancer 
 
 
                  mGPS  
 0 
n(%) 
1/2 
n(%) 
 
p-value 
 115 35  
Age    
    <75 65 (56) 17 (49)  
    >75 50 (44) 18 (51) 0.410 
Sex     
    Female 49 (43) 16 (46)  
    Male 66 (57) 19 (54) 0.746 
Mode of presentation    
    Emergency 1 (1) 3 (9)  
    Elective 114 (99) 32 (91) 0.040 
Tumour Site    
    Colon 69 (60) 25 (71)  
    Rectum  46 (40) 10 (29) 0.223 
T-stage    
    1 37 (32) 6 (17)  
    2 78 (68) 29 (83) 0.086 
Venous invasiona    
    Present 28 (27) 6 (19)  
    Absent 75 (73) 25 (81) 0.382 
Differentiation    
    Poor 3 (3) 0  
    Moderate/well 112 (97) 35 (100) 0.448 
Less than 12 lymph nodes     
    Yes 60 (52) 19 (54)  
    No 55 (48) 16 (46) 0.827 
Date of operation    
    2001 – 2004 52 (45) 18 (51)   
    2005 – 2008  63 (55) 17 (49) 0.520 
Mean OS     
    (months (95% CI)) 122 (112 – 131) 91 (71 – 110) 0.010 
 
 
a data complete for 134 (89%) patients 
 
 
